Claims for Patent: 7,947,272

Summary for Patent: 7,947,272

Title:	Compositions and methods of tolerizing a primate to an antigen
Abstract:	Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.
Inventor(s):	Frewin; Mark (Oxford, GB), Waldmann; Herman (Oxford, GB), Gorman; Scott (Whitney, GB), Hale; Geoff (Marston, GB), Rao; Patricia (Acton, MA), Kornaga; Tadeusz (Cambridge, MA), Ringler; Douglas (Boston, MA), Cobbold; Stephen (Witney, GB), Winsor-Hines; Dawn (Framingham, MA)
Assignee:	Tolerx, Inc. (Cambridge, MA) Isis Innovation, Ltd. (Oxford, GB) Cambridge University Technical Services, Ltd. (Cambridge, GB)
Application Number:	11/486,293
Patent Claims:	1. A method of treating a patent having an autoimmune disease selected from the group consisting of rheumatoid arthritis, systemic lupus, diabetes mellitus, and multiple sclerosis, said method comprising: treating the patient by administering to said patient an effective amount of a non-depleting anti-CD4 antibody, wherein said non-depleting anti-CD4 antibody has been modified to reduce binding to an Fc gamma receptor as compared to said antibody without the modification, and wherein said non-depleting anti-CD4 antibody comprises the light chain CDR sequences of FIG. 4C (SEQ ID NO:57) and the heavy chain CDR sequences of FIG. 4F (SEQ ID NO:60), wherein said antibody is administered alone or in combination with another compound. 2. The method of claim 1, wherein the anti-CD4 antibody comprises the light chain variable region sequence of FIG. 4C (SEQ ID NO: 57) and the heavy chain CDR sequences of FIG. 4F (SEQ ID NO: 60). 3. The method of claim 1, wherein the anti-CD4 antibody comprises the light chain CDR sequences of FIG. 4C (SEQ ID NO: 57) and the heavy chain variable region sequence of FIG. 4F (SEQ ID NO: 60). 4. The method of claim 1, wherein the anti-CD4 antibody comprises the light chain variable region sequence of FIG. 4C (SEQ ID NO: 57) and the heavy chain variable region sequence of FIG. 4F (SEQ ID NO: 60). 5. The method of claim 1, wherein the anti-CD4 antibody is a humanized antibody. 6. The method of claim 1, wherein the another compound is selected from an antibody which binds specifically to B cells, mycophenolate mofetil, anti-CD40, and anti-interferon-gamma. 7. The method of claim 6, wherein the another compound is an antibody which binds specifically to B cells. 8. The method of claim 7, wherein the antibody which binds specifically to B cells is rituximab. 9. A method of treating a patient having systemic lupus comprising: treating the patient by administering to the patient an effective amount of an anti-CD4 antibody which comprises the light chain CDR sequences of FIG. 4C (SEQ ID NO: 57) and the heavy chain CDR sequences of FIG. 4F (SEQ ID NO: 60) in combination with mycophenolate mofetil. 10. The method of claim 9, wherein the anti-CD4 antibody comprises the light chain variable region sequence of FIG. 4C (SEQ ID NO: 57) and the heavy chain CDR sequences of FIG. 4F (SEQ ID NO: 60). 11. The method of claim 9, wherein the anti-CD4 antibody comprises the light chain CDR sequences of FIG. 4C (SEQ ID NO: 57) and the heavy chain variable region sequence of FIG. 4F (SEQ ID NO: 60). 12. The method of claim 9, wherein the anti-CD4 antibody comprises the light chain variable region sequence of FIG. 4C (SEQ ID NO: 57) and the heavy chain variable region sequence of FIG. 4F (SEQ ID NO: 60). 13. The method of claim 9, wherein the anti-CD4 antibody is a humanized antibody. 14. The method of claim 9, wherein the anti-CD4 antibody comprises an Fc region that is aglycosylated. 15. The method of claim 9, wherein the anti-CD4 antibody comprises a constant region that does not comprise a glycosylation site. 16. The method of claim 1 wherein said non-depleting anti-CD4 antibody includes an Fc region that is aglycosylated. 17. The method of claim 1 wherein said non-depleting anti-CD4 antibody comprises a constant region that does not comprise a glycosylation site. 18. The method of claim 1 wherein the autoimmune disease is rheumatoid arthritis. 19. The method of claim 1 wherein the autoimmune disease is systemic lupus. 20. The method of claim 1 wherein the autoimmune disease is diabetes mellitus. 21. The method of claim 1 wherein the autoimmune disease is multiple sclerosis.

Details for Patent 7,947,272

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2021-06-14
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2021-06-14
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2021-06-14